Literature DB >> 9748032

Electromyography in cervical dystonia: changes after botulinum and trihexyphenidyl.

J W Brans1, M Aramideh, J H Koelman, R Lindeboom, J D Speelman, B W Ongerboer de Visser.   

Abstract

BACKGROUND: The value of physical examination in detecting involved neck muscles in cervical dystonia (CD) is uncertain and little is known about changes in electromyographic (EMG) features after botulinum toxin type A (BTA) treatment.
METHODS: In a double-blind, randomized study we recorded the EMG activities of 420 neck muscles in 42 patients with CD before and after treatment with BTA or trihexyphenidyl. We regarded any needle EMG activity higher than 100 microV as the gold standard for involuntary involvement of a muscle in the dystonic posture and compared this with the results of physical examination. We calculated EMG total scores by adding the scores of the individual muscles.
RESULTS: Physical examination had a low predictive value in the detection of involved muscles. There was a significant correlation between changes in EMG total scores and changes in clinical measurements. We observed increased EMG activity in 20% of noninjected muscles after BTA treatment and in 27% of noninjected muscles after trihexyphenidyl treatment. A switch from one most active muscle to another was seen equally in both groups and had no influence on clinical response.
CONCLUSION: Physical examination alone is not sufficient to detect involved muscles, and repeated, simultaneous EMG-guided application of BTA may be helpful. In addition to clinical measurements, changes in EMG activity due to treatment can be used as a physiologic measure in evaluating treatment response. Increased activity of noninjected muscles and a switch from one most active muscle to another are not related to BTA treatment, but are probably pathophysiologic phenomena of CD itself.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9748032     DOI: 10.1212/wnl.51.3.815

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

Review 1.  Botulinum toxin type A versus anticholinergics for cervical dystonia.

Authors:  J Costa; C Espírito-Santo; A Borges; J J Ferreira; M Coelho; C Sampaio
Journal:  Cochrane Database Syst Rev       Date:  2005-01-25

Review 2.  Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin.

Authors:  Maria Fiorella Contarino; Joost Van Den Dool; Yacov Balash; Kailash Bhatia; Nir Giladi; Johannes H Koelman; Annemette Lokkegaard; Maria J Marti; Miranda Postma; Maja Relja; Matej Skorvanek; Johannes D Speelman; Evelien Zoons; Joaquim J Ferreira; Marie Vidailhet; Alberto Albanese; Marina A J Tijssen
Journal:  Front Neurol       Date:  2017-02-24       Impact factor: 4.003

Review 3.  Update on treatments for dystonia.

Authors:  D Cristopher Bragg; Nutan Sharma
Journal:  Curr Neurol Neurosci Rep       Date:  2014-06       Impact factor: 5.081

4.  Botulinum toxin type A versus anticholinergics for cervical dystonia.

Authors:  Filipe B Rodrigues; Gonçalo S Duarte; Mafalda Castelão; Raquel E Marques; Joaquim Ferreira; Cristina Sampaio; Austen P Moore; João Costa
Journal:  Cochrane Database Syst Rev       Date:  2021-04-14

5.  Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE).

Authors:  Joseph Jankovic; Charles H Adler; P David Charles; Cynthia Comella; Mark Stacy; Marc Schwartz; Susan M Sutch; Mitchell F Brin; Spyridon Papapetropoulos
Journal:  BMC Neurol       Date:  2011-11-04       Impact factor: 2.474

Review 6.  Botulinum Toxin in Movement Disorders: An Update.

Authors:  Charenya Anandan; Joseph Jankovic
Journal:  Toxins (Basel)       Date:  2021-01-08       Impact factor: 4.546

7.  Botulinum toxin type A in the treatment of patients with cervical dystonia.

Authors:  Allison Brashear
Journal:  Biologics       Date:  2009-07-13

8.  Threshold of Clinical Severity of Cervical Dystonia for Positive (18)F-FDG PET/CT.

Authors:  Hyun Jung Lee; Young-Sil An; Young-Whan Ahn; Shin-Young Yim
Journal:  Ann Rehabil Med       Date:  2013-12-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.